ReCode Therapeutics is a clinical-stage genetic medicines company using its proprietary Selective Organ Targeting (SORT) lipid nanoparticle platform to deliver mRNA and gene correction therapeutics directly to the lungs and other organs beyond the liver. Its lead programs target cystic fibrosis and primary ciliary dyskinesia, rare genetically defined diseases with no existing treatment options.
Advance inhaled mRNA programs for cystic fibrosis and primary ciliary dyskinesia through the clinic
Expanded gene correction pipeline from Cystic Fibrosis Foundation-backed funding
After achieving clinical validation earlier this year, ReCode Therapeutics has called up a new CEO, Heather Clark, to take on the mission of advancing programs for cystic fibrosis and primary ciliary dyskinesia through the clinic.
Chief Executive Officer (since August 2026)
Executive Chair of the Board
Chief Medical Officer
Chief Scientific Officer